Ocular Therapeutix, Inc.
OCUL
$11.87
-$0.43-3.50%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 56.66M | 59.65M | 63.72M | 61.44M | 61.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 56.66M | 59.65M | 63.72M | 61.44M | 61.10M |
| Cost of Revenue | 177.98M | 155.32M | 133.26M | 108.62M | 86.40M |
| Gross Profit | -121.31M | -95.67M | -69.54M | -47.18M | -25.31M |
| SG&A Expenses | 106.82M | 99.71M | 93.54M | 85.37M | 80.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 284.80M | 255.03M | 226.80M | 194.00M | 166.87M |
| Operating Income | -228.13M | -195.38M | -163.08M | -132.56M | -105.77M |
| Income Before Tax | -216.75M | -192.71M | -193.51M | -174.34M | -138.36M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -216.75 | -192.71 | -193.51 | -174.34 | -138.36 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -216.75M | -192.71M | -193.51M | -174.34M | -138.36M |
| EBIT | -228.13M | -195.38M | -163.08M | -132.56M | -105.77M |
| EBITDA | -224.21M | -191.53M | -159.29M | -128.76M | -102.05M |
| EPS Basic | -1.28 | -1.15 | -1.26 | -1.32 | -1.11 |
| Normalized Basic EPS | -0.80 | -0.69 | -0.62 | -0.66 | -0.64 |
| EPS Diluted | -1.28 | -1.15 | -1.26 | -1.32 | -1.35 |
| Normalized Diluted EPS | -0.80 | -0.69 | -0.62 | -0.66 | -0.63 |
| Average Basic Shares Outstanding | 677.00M | 670.23M | 632.86M | 549.27M | 461.65M |
| Average Diluted Shares Outstanding | 677.00M | 670.23M | 632.86M | 549.27M | 467.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |